Safety and Efficacy of EUS-RFA in Pancreatic Insulinoma
Recruiting · NCT07585032 · Observational (researchers observe without assigning treatment) · Lead sponsor: Sahlgrenska University Hospital
View the official record on ClinicalTrials.gov →Interventions studied
EUS-RFA
What this trial is about
Transcutaneous and EUS-guided radiofrequency ablation are both modern modalities to apply in the managemnet of various malignancies. In the current study the investigators aim to study the technical feasibility, patient safety and clinical efficacy of EUS-RFA for the treatment of pancreatic insulinoma.
Who can take part
Age range
15 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Insulinoma verified by pathology (often from EUS-FNB-sampling)
Exclusion criteria
- Patients unwilling to participate
- Patients unable to understand and obtain written informed conscent
- Severe comorbidity
Where it is running
1 location listed.
- Sahlgrenska Univeristy Hospital - Gothenburg, Sweden